Vancomycin: biosynthesis, clinical uses & adverse effects
Saved in:
| Other Authors: | |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
New York
Nova Science Publishers
2014
|
| Series: | Pharmacology - Research, Safety Testing and Regulation
|
| Subjects: | |
| Online Access: | TUM01 |
| Item Description: | Print version record |
| Physical Description: | 1 online resource |
| ISBN: | 9781629485706 1629485705 |
Staff View
MARC
| LEADER | 00000nmm a2200000zc 4500 | ||
|---|---|---|---|
| 001 | BV044358098 | ||
| 003 | DE-604 | ||
| 005 | 20180307 | ||
| 007 | cr|uuu---uuuuu | ||
| 008 | 170620s2014 |||| o||u| ||||||eng d | ||
| 020 | |a 9781629485706 |9 978-1-62948-570-6 | ||
| 020 | |a 1629485705 |9 1-62948-570-5 | ||
| 035 | |a (ZDB-4-NLEBK)ocn869932411 | ||
| 035 | |a (OCoLC)869932411 | ||
| 035 | |a (DE-599)BVBBV044358098 | ||
| 040 | |a DE-604 |b ger |e rda | ||
| 041 | 0 | |a eng | |
| 049 | |a DE-91 | ||
| 082 | 0 | |a 615.329 |2 23 | |
| 245 | 1 | 0 | |a Vancomycin |b biosynthesis, clinical uses & adverse effects |c edited by Abu Gafar Hossion |
| 264 | 1 | |a New York |b Nova Science Publishers |c 2014 | |
| 300 | |a 1 online resource | ||
| 336 | |b txt |2 rdacontent | ||
| 337 | |b c |2 rdamedia | ||
| 338 | |b cr |2 rdacarrier | ||
| 490 | 0 | |a Pharmacology - Research, Safety Testing and Regulation | |
| 500 | |a Print version record | ||
| 505 | 8 | |a There have been news reports with the tales of many community acquired bacterial infections that lead to serious hospitalization. The last resort drug for these infections is vancomycin; an FDA approved glycopeptide antibiotic for the treatment of several bacterial infections, including infections caused by susceptible staphylococcus, streptococcus, enterococcus, and diphtheroid organisms. Around the world in 1997, initial reports of reduced vancomycin susceptibility in clinical isolates of staphylococcus aureus generated significant concern in the medical community. There has been uncertainty | |
| 505 | 8 | |a VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter 1: Pharmacodynamic Dosing of Vancomycin: Concepts and Clinical Evidence; Abstract; A Brief History of Vancomycin; Vancomycin Pharmacokinetics and Pharmacodynamics; Vancomycin: A Consensus Review; Clinical Benefit from Higher Trough Goals; Higher Trough Goals: More Harm than Good?; AUC/MIC Ratio or Trough Concentrations: Where Should the Focus Be? | |
| 505 | 8 | |a Individualization of Doses: Calculating Doses, Estimating Troughs, and Estimating AUCConclusion; References; Chapter 2: Comparative and Functional Genomics as Tools for Understanding Vancomycin Resistance in Bacteria; Abstract; Introduction; Comparative Genomics and Vancomycin Resistance; Functional Genomics and Vancomycin Resistance; References; Chapter 3: Vancomycin: Use, Dosing and Therapeutic Drug Monitoring; Abstract; Introduction; Indications and Efficacy; Toxicity; Drug Interactions; Analytical Methods; Pharmacokinetics and Pharmacodynamics; Dosing; Therapeutic Drug Monitoring | |
| 505 | 8 | |a ConclusionAcknowledgments; References; Chapter 4: Clinical Use of Vancomycinin Cardiovascular Homograft Banking; Abstract; Introduction; Bioburden Reduction of Homografts; Emerging Importance of Vancomycin in Tissue Banking; Benefits and Concerns of Residual Antibiotics; Conclusion; References; Chapter 5: Common and Uncommon Adverse Effects of Vancomycin; Abstract; Introduction; Vancomycin-related Nephrotoxicity; Vancomycin-related Skin Reactions; Vancomycin-related Ototoxicity; OTHER ADVERSE EFFECTS; Conclusion; Acknowledgments; REFERENCES | |
| 505 | 8 | |a Chapter 6: Clinical Use of Vancomycin in Methicillin-Resistant S. Aureus or Coagulase-Negative Staphylococci Bacteremia, Catheter-Related Bacteremia and EndocarditisAbstract; Introduction; Methicillin-Resistant Staphylococci Primary Bacteremia; Methicillin-Resistant Staphylococci Catheter-Related Bacteremia; Methicillin-Resistant Staphylococci Endocarditis; Conclusion; References; Chapter 7: Clinical Use of Vancomycin in MRSA Ventilator-Associated Pneumonia; Abstract; Introduction; Epidemiology; Risk Factors; Morbidity/Mortality/Cost; Treatment; Conclusion; References | |
| 505 | 8 | |a Chapter 8: Clinical Use of Vancomycin in Methicillin-Resistant Staphylococci Bone and Joint InfectionAbstract; Introduction; Intermittent or Continuous Infusion of Vancomycin; Use of Vancomycin as Definite Therapy; Conclusion; Acknowledgments; References; Index | |
| 650 | 7 | |a MEDICAL / Pharmacology |2 bisacsh | |
| 650 | 7 | |a Vancomycin |2 fast | |
| 650 | 4 | |a Vancomycin / Therapeutic use | |
| 650 | 4 | |a Medizin | |
| 650 | 4 | |a Vancomycin | |
| 700 | 1 | |a Hossion, Abu Gafar |4 edt | |
| 776 | 0 | 8 | |i Erscheint auch als |n Druck-Ausgabe |t Vancomycin |z 9781629485591 |
| 912 | |a ZDB-4-NLEBK | ||
| 999 | |a oai:aleph.bib-bvb.de:BVB01-029760729 | ||
| 966 | e | |u https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=664118 |l TUM01 |p ZDB-4-NLEBK |q TUM_PDA_EBSCOMED_Kauf |x Aggregator |3 Volltext | |
Record in the Search Index
| _version_ | 1804177603603464192 |
|---|---|
| any_adam_object | |
| author2 | Hossion, Abu Gafar |
| author2_role | edt |
| author2_variant | a g h ag agh |
| author_facet | Hossion, Abu Gafar |
| building | Verbundindex |
| bvnumber | BV044358098 |
| collection | ZDB-4-NLEBK |
| contents | There have been news reports with the tales of many community acquired bacterial infections that lead to serious hospitalization. The last resort drug for these infections is vancomycin; an FDA approved glycopeptide antibiotic for the treatment of several bacterial infections, including infections caused by susceptible staphylococcus, streptococcus, enterococcus, and diphtheroid organisms. Around the world in 1997, initial reports of reduced vancomycin susceptibility in clinical isolates of staphylococcus aureus generated significant concern in the medical community. There has been uncertainty VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter 1: Pharmacodynamic Dosing of Vancomycin: Concepts and Clinical Evidence; Abstract; A Brief History of Vancomycin; Vancomycin Pharmacokinetics and Pharmacodynamics; Vancomycin: A Consensus Review; Clinical Benefit from Higher Trough Goals; Higher Trough Goals: More Harm than Good?; AUC/MIC Ratio or Trough Concentrations: Where Should the Focus Be? Individualization of Doses: Calculating Doses, Estimating Troughs, and Estimating AUCConclusion; References; Chapter 2: Comparative and Functional Genomics as Tools for Understanding Vancomycin Resistance in Bacteria; Abstract; Introduction; Comparative Genomics and Vancomycin Resistance; Functional Genomics and Vancomycin Resistance; References; Chapter 3: Vancomycin: Use, Dosing and Therapeutic Drug Monitoring; Abstract; Introduction; Indications and Efficacy; Toxicity; Drug Interactions; Analytical Methods; Pharmacokinetics and Pharmacodynamics; Dosing; Therapeutic Drug Monitoring ConclusionAcknowledgments; References; Chapter 4: Clinical Use of Vancomycinin Cardiovascular Homograft Banking; Abstract; Introduction; Bioburden Reduction of Homografts; Emerging Importance of Vancomycin in Tissue Banking; Benefits and Concerns of Residual Antibiotics; Conclusion; References; Chapter 5: Common and Uncommon Adverse Effects of Vancomycin; Abstract; Introduction; Vancomycin-related Nephrotoxicity; Vancomycin-related Skin Reactions; Vancomycin-related Ototoxicity; OTHER ADVERSE EFFECTS; Conclusion; Acknowledgments; REFERENCES Chapter 6: Clinical Use of Vancomycin in Methicillin-Resistant S. Aureus or Coagulase-Negative Staphylococci Bacteremia, Catheter-Related Bacteremia and EndocarditisAbstract; Introduction; Methicillin-Resistant Staphylococci Primary Bacteremia; Methicillin-Resistant Staphylococci Catheter-Related Bacteremia; Methicillin-Resistant Staphylococci Endocarditis; Conclusion; References; Chapter 7: Clinical Use of Vancomycin in MRSA Ventilator-Associated Pneumonia; Abstract; Introduction; Epidemiology; Risk Factors; Morbidity/Mortality/Cost; Treatment; Conclusion; References Chapter 8: Clinical Use of Vancomycin in Methicillin-Resistant Staphylococci Bone and Joint InfectionAbstract; Introduction; Intermittent or Continuous Infusion of Vancomycin; Use of Vancomycin as Definite Therapy; Conclusion; Acknowledgments; References; Index |
| ctrlnum | (ZDB-4-NLEBK)ocn869932411 (OCoLC)869932411 (DE-599)BVBBV044358098 |
| dewey-full | 615.329 |
| dewey-hundreds | 600 - Technology (Applied sciences) |
| dewey-ones | 615 - Pharmacology and therapeutics |
| dewey-raw | 615.329 |
| dewey-search | 615.329 |
| dewey-sort | 3615.329 |
| dewey-tens | 610 - Medicine and health |
| discipline | Medizin |
| format | Electronic eBook |
| fullrecord | <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>04638nmm a2200481zc 4500</leader><controlfield tag="001">BV044358098</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20180307 </controlfield><controlfield tag="007">cr|uuu---uuuuu</controlfield><controlfield tag="008">170620s2014 |||| o||u| ||||||eng d</controlfield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9781629485706</subfield><subfield code="9">978-1-62948-570-6</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">1629485705</subfield><subfield code="9">1-62948-570-5</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ZDB-4-NLEBK)ocn869932411</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)869932411</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)BVBBV044358098</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rda</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-91</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">615.329</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Vancomycin</subfield><subfield code="b">biosynthesis, clinical uses & adverse effects</subfield><subfield code="c">edited by Abu Gafar Hossion</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">New York</subfield><subfield code="b">Nova Science Publishers</subfield><subfield code="c">2014</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="490" ind1="0" ind2=" "><subfield code="a">Pharmacology - Research, Safety Testing and Regulation</subfield></datafield><datafield tag="500" ind1=" " ind2=" "><subfield code="a">Print version record</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">There have been news reports with the tales of many community acquired bacterial infections that lead to serious hospitalization. The last resort drug for these infections is vancomycin; an FDA approved glycopeptide antibiotic for the treatment of several bacterial infections, including infections caused by susceptible staphylococcus, streptococcus, enterococcus, and diphtheroid organisms. Around the world in 1997, initial reports of reduced vancomycin susceptibility in clinical isolates of staphylococcus aureus generated significant concern in the medical community. There has been uncertainty</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter 1: Pharmacodynamic Dosing of Vancomycin: Concepts and Clinical Evidence; Abstract; A Brief History of Vancomycin; Vancomycin Pharmacokinetics and Pharmacodynamics; Vancomycin: A Consensus Review; Clinical Benefit from Higher Trough Goals; Higher Trough Goals: More Harm than Good?; AUC/MIC Ratio or Trough Concentrations: Where Should the Focus Be?</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Individualization of Doses: Calculating Doses, Estimating Troughs, and Estimating AUCConclusion; References; Chapter 2: Comparative and Functional Genomics as Tools for Understanding Vancomycin Resistance in Bacteria; Abstract; Introduction; Comparative Genomics and Vancomycin Resistance; Functional Genomics and Vancomycin Resistance; References; Chapter 3: Vancomycin: Use, Dosing and Therapeutic Drug Monitoring; Abstract; Introduction; Indications and Efficacy; Toxicity; Drug Interactions; Analytical Methods; Pharmacokinetics and Pharmacodynamics; Dosing; Therapeutic Drug Monitoring</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">ConclusionAcknowledgments; References; Chapter 4: Clinical Use of Vancomycinin Cardiovascular Homograft Banking; Abstract; Introduction; Bioburden Reduction of Homografts; Emerging Importance of Vancomycin in Tissue Banking; Benefits and Concerns of Residual Antibiotics; Conclusion; References; Chapter 5: Common and Uncommon Adverse Effects of Vancomycin; Abstract; Introduction; Vancomycin-related Nephrotoxicity; Vancomycin-related Skin Reactions; Vancomycin-related Ototoxicity; OTHER ADVERSE EFFECTS; Conclusion; Acknowledgments; REFERENCES</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter 6: Clinical Use of Vancomycin in Methicillin-Resistant S. Aureus or Coagulase-Negative Staphylococci Bacteremia, Catheter-Related Bacteremia and EndocarditisAbstract; Introduction; Methicillin-Resistant Staphylococci Primary Bacteremia; Methicillin-Resistant Staphylococci Catheter-Related Bacteremia; Methicillin-Resistant Staphylococci Endocarditis; Conclusion; References; Chapter 7: Clinical Use of Vancomycin in MRSA Ventilator-Associated Pneumonia; Abstract; Introduction; Epidemiology; Risk Factors; Morbidity/Mortality/Cost; Treatment; Conclusion; References</subfield></datafield><datafield tag="505" ind1="8" ind2=" "><subfield code="a">Chapter 8: Clinical Use of Vancomycin in Methicillin-Resistant Staphylococci Bone and Joint InfectionAbstract; Introduction; Intermittent or Continuous Infusion of Vancomycin; Use of Vancomycin as Definite Therapy; Conclusion; Acknowledgments; References; Index</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">MEDICAL / Pharmacology</subfield><subfield code="2">bisacsh</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Vancomycin</subfield><subfield code="2">fast</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vancomycin / Therapeutic use</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Medizin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vancomycin</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hossion, Abu Gafar</subfield><subfield code="4">edt</subfield></datafield><datafield tag="776" ind1="0" ind2="8"><subfield code="i">Erscheint auch als</subfield><subfield code="n">Druck-Ausgabe</subfield><subfield code="t">Vancomycin</subfield><subfield code="z">9781629485591</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-4-NLEBK</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-029760729</subfield></datafield><datafield tag="966" ind1="e" ind2=" "><subfield code="u">https://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&AN=664118</subfield><subfield code="l">TUM01</subfield><subfield code="p">ZDB-4-NLEBK</subfield><subfield code="q">TUM_PDA_EBSCOMED_Kauf</subfield><subfield code="x">Aggregator</subfield><subfield code="3">Volltext</subfield></datafield></record></collection> |
| id | DE-604.BV044358098 |
| illustrated | Not Illustrated |
| indexdate | 2024-07-10T07:50:42Z |
| institution | BVB |
| isbn | 9781629485706 1629485705 |
| language | English |
| oai_aleph_id | oai:aleph.bib-bvb.de:BVB01-029760729 |
| oclc_num | 869932411 |
| open_access_boolean | |
| owner | DE-91 DE-BY-TUM |
| owner_facet | DE-91 DE-BY-TUM |
| physical | 1 online resource |
| psigel | ZDB-4-NLEBK ZDB-4-NLEBK TUM_PDA_EBSCOMED_Kauf |
| publishDate | 2014 |
| publishDateSearch | 2014 |
| publishDateSort | 2014 |
| publisher | Nova Science Publishers |
| record_format | marc |
| series2 | Pharmacology - Research, Safety Testing and Regulation |
| spelling | Vancomycin biosynthesis, clinical uses & adverse effects edited by Abu Gafar Hossion New York Nova Science Publishers 2014 1 online resource txt rdacontent c rdamedia cr rdacarrier Pharmacology - Research, Safety Testing and Regulation Print version record There have been news reports with the tales of many community acquired bacterial infections that lead to serious hospitalization. The last resort drug for these infections is vancomycin; an FDA approved glycopeptide antibiotic for the treatment of several bacterial infections, including infections caused by susceptible staphylococcus, streptococcus, enterococcus, and diphtheroid organisms. Around the world in 1997, initial reports of reduced vancomycin susceptibility in clinical isolates of staphylococcus aureus generated significant concern in the medical community. There has been uncertainty VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter 1: Pharmacodynamic Dosing of Vancomycin: Concepts and Clinical Evidence; Abstract; A Brief History of Vancomycin; Vancomycin Pharmacokinetics and Pharmacodynamics; Vancomycin: A Consensus Review; Clinical Benefit from Higher Trough Goals; Higher Trough Goals: More Harm than Good?; AUC/MIC Ratio or Trough Concentrations: Where Should the Focus Be? Individualization of Doses: Calculating Doses, Estimating Troughs, and Estimating AUCConclusion; References; Chapter 2: Comparative and Functional Genomics as Tools for Understanding Vancomycin Resistance in Bacteria; Abstract; Introduction; Comparative Genomics and Vancomycin Resistance; Functional Genomics and Vancomycin Resistance; References; Chapter 3: Vancomycin: Use, Dosing and Therapeutic Drug Monitoring; Abstract; Introduction; Indications and Efficacy; Toxicity; Drug Interactions; Analytical Methods; Pharmacokinetics and Pharmacodynamics; Dosing; Therapeutic Drug Monitoring ConclusionAcknowledgments; References; Chapter 4: Clinical Use of Vancomycinin Cardiovascular Homograft Banking; Abstract; Introduction; Bioburden Reduction of Homografts; Emerging Importance of Vancomycin in Tissue Banking; Benefits and Concerns of Residual Antibiotics; Conclusion; References; Chapter 5: Common and Uncommon Adverse Effects of Vancomycin; Abstract; Introduction; Vancomycin-related Nephrotoxicity; Vancomycin-related Skin Reactions; Vancomycin-related Ototoxicity; OTHER ADVERSE EFFECTS; Conclusion; Acknowledgments; REFERENCES Chapter 6: Clinical Use of Vancomycin in Methicillin-Resistant S. Aureus or Coagulase-Negative Staphylococci Bacteremia, Catheter-Related Bacteremia and EndocarditisAbstract; Introduction; Methicillin-Resistant Staphylococci Primary Bacteremia; Methicillin-Resistant Staphylococci Catheter-Related Bacteremia; Methicillin-Resistant Staphylococci Endocarditis; Conclusion; References; Chapter 7: Clinical Use of Vancomycin in MRSA Ventilator-Associated Pneumonia; Abstract; Introduction; Epidemiology; Risk Factors; Morbidity/Mortality/Cost; Treatment; Conclusion; References Chapter 8: Clinical Use of Vancomycin in Methicillin-Resistant Staphylococci Bone and Joint InfectionAbstract; Introduction; Intermittent or Continuous Infusion of Vancomycin; Use of Vancomycin as Definite Therapy; Conclusion; Acknowledgments; References; Index MEDICAL / Pharmacology bisacsh Vancomycin fast Vancomycin / Therapeutic use Medizin Vancomycin Hossion, Abu Gafar edt Erscheint auch als Druck-Ausgabe Vancomycin 9781629485591 |
| spellingShingle | Vancomycin biosynthesis, clinical uses & adverse effects There have been news reports with the tales of many community acquired bacterial infections that lead to serious hospitalization. The last resort drug for these infections is vancomycin; an FDA approved glycopeptide antibiotic for the treatment of several bacterial infections, including infections caused by susceptible staphylococcus, streptococcus, enterococcus, and diphtheroid organisms. Around the world in 1997, initial reports of reduced vancomycin susceptibility in clinical isolates of staphylococcus aureus generated significant concern in the medical community. There has been uncertainty VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; VANCOMYCIN: BIOSYNTHESIS, CLINICAL USES AND ADVERSE EFFECTS; Library of Congress Cataloging-in-Publication Data; Contents; Preface; Chapter 1: Pharmacodynamic Dosing of Vancomycin: Concepts and Clinical Evidence; Abstract; A Brief History of Vancomycin; Vancomycin Pharmacokinetics and Pharmacodynamics; Vancomycin: A Consensus Review; Clinical Benefit from Higher Trough Goals; Higher Trough Goals: More Harm than Good?; AUC/MIC Ratio or Trough Concentrations: Where Should the Focus Be? Individualization of Doses: Calculating Doses, Estimating Troughs, and Estimating AUCConclusion; References; Chapter 2: Comparative and Functional Genomics as Tools for Understanding Vancomycin Resistance in Bacteria; Abstract; Introduction; Comparative Genomics and Vancomycin Resistance; Functional Genomics and Vancomycin Resistance; References; Chapter 3: Vancomycin: Use, Dosing and Therapeutic Drug Monitoring; Abstract; Introduction; Indications and Efficacy; Toxicity; Drug Interactions; Analytical Methods; Pharmacokinetics and Pharmacodynamics; Dosing; Therapeutic Drug Monitoring ConclusionAcknowledgments; References; Chapter 4: Clinical Use of Vancomycinin Cardiovascular Homograft Banking; Abstract; Introduction; Bioburden Reduction of Homografts; Emerging Importance of Vancomycin in Tissue Banking; Benefits and Concerns of Residual Antibiotics; Conclusion; References; Chapter 5: Common and Uncommon Adverse Effects of Vancomycin; Abstract; Introduction; Vancomycin-related Nephrotoxicity; Vancomycin-related Skin Reactions; Vancomycin-related Ototoxicity; OTHER ADVERSE EFFECTS; Conclusion; Acknowledgments; REFERENCES Chapter 6: Clinical Use of Vancomycin in Methicillin-Resistant S. Aureus or Coagulase-Negative Staphylococci Bacteremia, Catheter-Related Bacteremia and EndocarditisAbstract; Introduction; Methicillin-Resistant Staphylococci Primary Bacteremia; Methicillin-Resistant Staphylococci Catheter-Related Bacteremia; Methicillin-Resistant Staphylococci Endocarditis; Conclusion; References; Chapter 7: Clinical Use of Vancomycin in MRSA Ventilator-Associated Pneumonia; Abstract; Introduction; Epidemiology; Risk Factors; Morbidity/Mortality/Cost; Treatment; Conclusion; References Chapter 8: Clinical Use of Vancomycin in Methicillin-Resistant Staphylococci Bone and Joint InfectionAbstract; Introduction; Intermittent or Continuous Infusion of Vancomycin; Use of Vancomycin as Definite Therapy; Conclusion; Acknowledgments; References; Index MEDICAL / Pharmacology bisacsh Vancomycin fast Vancomycin / Therapeutic use Medizin Vancomycin |
| title | Vancomycin biosynthesis, clinical uses & adverse effects |
| title_auth | Vancomycin biosynthesis, clinical uses & adverse effects |
| title_exact_search | Vancomycin biosynthesis, clinical uses & adverse effects |
| title_full | Vancomycin biosynthesis, clinical uses & adverse effects edited by Abu Gafar Hossion |
| title_fullStr | Vancomycin biosynthesis, clinical uses & adverse effects edited by Abu Gafar Hossion |
| title_full_unstemmed | Vancomycin biosynthesis, clinical uses & adverse effects edited by Abu Gafar Hossion |
| title_short | Vancomycin |
| title_sort | vancomycin biosynthesis clinical uses adverse effects |
| title_sub | biosynthesis, clinical uses & adverse effects |
| topic | MEDICAL / Pharmacology bisacsh Vancomycin fast Vancomycin / Therapeutic use Medizin Vancomycin |
| topic_facet | MEDICAL / Pharmacology Vancomycin Vancomycin / Therapeutic use Medizin |
| work_keys_str_mv | AT hossionabugafar vancomycinbiosynthesisclinicalusesadverseeffects |